ABT: having cured 52 of 53 GT1a and 24 of 24 GT1b, ABT has already addressed the lion's share of difficult to treat HCV patients. Most likely, they will do an add-on study if it is economically advantageous. One would guess that such stellar results would foretell the result in additional studies. Genotype 1 is the standard.
Market Data 
Markets 
AI
